0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.7 mg/ml (Please refer to the vial label for the specific concentration.)
Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human PTGFRN. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Prostaglandin F2 Receptor Inhibitor,Cd315,Cd9P-1,Ewi-F,Fprp,Smap-6,Ptgfrn
Endoplasmic reticulum membrane; Single-pass type I membrane protein , Golgi apparatus , trans-Golgi network membrane; Single-pass type I membrane protein
Inhibits the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, by decreasing the receptor number rather than the affinity constant. Functional coupling with the prostaglandin F2-alpha receptor seems to occur.